Danni L. Harris

ORCID: 0000-0003-4231-1926

Pharmacology, Toxicology and PharmaceuticsBiochemistry, Genetics and Molecular BiologyNeuroscienceChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “The development of diphenyleneiodonium analogs as GPR3 agonists”.

The development of diphenyleneiodonium analogs as GPR3 agonists

Bioorganic & Medicinal Chemistry Letters(2023)10.1016/j.bmcl.2023.129427

N/A

0.360DataRank · unranked

10 citations

Danni L. Harris, Joseph W. Wilson, Bruce E. Blough, Elaine A. Gay

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Bioorganic & Medicinal Chemistry(2021)10.1016/j.bmc.2021.116215

N/A

0DataRank · unranked

16 citations

Thomas F. Gamage, Ann M. Decker, David B. Finlay, Tiffany L. Langston, Daniel G. Barrus +4 more

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

European Journal of Medicinal Chemistry(2022)10.1016/j.ejmech.2022.114741

N/A

0DataRank · unranked

10 citations

Ann M. Decker, Kristen Woodhouse, Rodney W. Snyder, Purvi R. Patel, Danni L. Harris +4 more

Design, Synthesis, and Structure–Activity Relationship Studies of Novel GPR88 Agonists (4-Substituted-phenyl)acetamides Based on the Reversed Amide Scaffold

ACS Chemical Neuroscience(2023)10.1021/acschemneuro.3c00684

N/A

0DataRank · unranked

6 citations

Dongliang Guan, Hetti Handi Chaminda Lakmal, Ann M. Decker, Gregory H. Imler, Andrew T. Kerr +3 more